Lilly Endowment’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$108B Sell
90,376,978
-1,520,000
-2% -$1.55B 100% 1
2026
Q1
$84.5B Sell
91,896,978
-293,538
-0.3% -$298M 100% 1
2025
Q4
$99.1B Sell
92,190,516
-3,302,477
-3% -$3.16B 100% 1
2025
Q3
$72.9B Sell
95,492,993
-523,985
-0.5% -$390M 100% 1
2025
Q2
$74.8B Hold
96,016,978
100% 1
2025
Q1
$79.3B Sell
96,016,978
-875,000
-0.9% -$728M 100% 1
2024
Q4
$74.8B Hold
96,891,978
100% 1
2024
Q3
$85.8B Sell
96,891,978
-475,391
-0.5% -$427M 100% 1
2024
Q2
$88.2B Sell
97,367,369
-1,531,441
-2% -$1.23B 100% 1
2024
Q1
$76.9B Sell
98,898,810
-870,000
-0.9% -$619M 100% 1
2023
Q4
$58.2B Sell
99,768,810
-215,000
-0.2% -$125M 100% 1
2023
Q3
$53.7B Sell
99,983,810
-1,045,000
-1% -$538M 100% 1
2023
Q2
$47.4B Sell
101,028,810
-1,515,000
-1% -$635M 100% 1
2023
Q1
$35.2B Sell
102,543,810
-405,000
-0.4% -$137M 100% 1
2022
Q4
$37.7B Sell
102,948,810
-825,000
-0.8% -$293M 100% 1
2022
Q3
$33.6B Sell
103,773,810
-387,243
-0.4% -$123M 100% 1
2022
Q2
$33.8B Sell
104,161,053
-1,993,133
-2% -$598M 100% 1
2022
Q1
$30.4B Sell
106,154,186
-1,309,624
-1% -$337M 100% 1
2021
Q4
$29.7B Sell
107,463,810
-784,800
-0.7% -$199M 100% 1
2021
Q3
$25B Sell
108,248,610
-1,150,592
-1% -$284M 100% 1
2021
Q2
$25.1B Sell
109,399,202
-902,898
-0.8% -$181M 100% 1
2021
Q1
$20.6B Sell
110,302,100
-830,243
-0.7% -$162M 100% 1
2020
Q4
$18.8B Hold
111,132,343
100% 1
2020
Q3
$16.4B Sell
111,132,343
-427,961
-0.4% -$66.2M 100% 1
2020
Q2
$18.3B Sell
111,560,304
-1,711,038
-2% -$263M 100% 1
2020
Q1
$15.7B Sell
113,271,342
-1,289,257
-1% -$177M 100% 1
2019
Q4
$15.1B Sell
114,560,599
-2,039,705
-2% -$236M 100% 1
2019
Q3
$13B Sell
116,600,304
-210,000
-0.2% -$23.4M 100% 1
2019
Q2
$12.9B Hold
116,810,304
100% 1
2019
Q1
$15.2B Sell
116,810,304
-1,205,000
-1% -$147M 100% 1
2018
Q4
$13.7B Sell
118,015,304
-1,385,500
-1% -$155M 100% 1
2018
Q3
$12.8B Sell
119,400,804
-2,650,000
-2% -$265M 100% 1
2018
Q2
$10.4B Sell
122,050,804
-1,025,000
-0.8% -$84.2M 100% 1
2018
Q1
$9.52B Hold
123,075,804
100% 1
2017
Q4
$10.4B Sell
123,075,804
-405,000
-0.3% -$34.5M 100% 1
2017
Q3
$10.6B Sell
123,480,804
-785,000
-0.6% -$64.4M 100% 1
2017
Q2
$10.2B Sell
124,265,804
-425,000
-0.3% -$34.7M 100% 1
2017
Q1
$10.5B Sell
124,690,804
-885,000
-0.7% -$70.9M 100% 1
2016
Q4
$9.24B Sell
125,575,804
-200,000
-0.2% -$14.9M 100% 1
2016
Q3
$10.1B Sell
125,775,804
-880,000
-0.7% -$70.4M 100% 1
2016
Q2
$9.97B Sell
126,655,804
-1,205,000
-0.9% -$90.7M 100% 1
2016
Q1
$9.21B Hold
127,860,804
100% 1
2015
Q4
$10.8B Sell
127,860,804
-1,510,000
-1% -$125M 100% 1
2015
Q3
$10.8B Sell
129,370,804
-250,000
-0.2% -$21.1M 100% 1
2015
Q2
$10.8B Sell
129,620,804
-1,415,000
-1% -$108M 100% 1
2015
Q1
$9.52B Sell
131,035,804
-370,000
-0.3% -$26.3M 100% 1
2014
Q4
$9.07B Sell
131,405,804
-1,325,000
-1% -$89.4M 100% 1
2014
Q3
$8.61B Sell
132,730,804
-1,095,000
-0.8% -$69.3M 100% 1
2014
Q2
$8.32B Sell
133,825,804
-1,845,000
-1% -$110M 100% 1
2014
Q1
$7.99B Hold
135,670,804
100% 1
2013
Q4
$6.92B Hold
135,670,804
100% 1
2013
Q3
$6.83B Hold
135,670,804
100% 1
2013
Q2
$6.66B Buy
+135,670,804
New +$7.38B 100% 1

Other funds holding LLY

Lilly Endowment's LLY Position: Q2 2026 in Review

Lilly Endowment reduced its Eli Lilly (LLY) stake by 1.7% in Q2 2026, selling an estimated $1.55B and leaving 90,376,978 shares worth $108B. The position accounts for 100% of the portfolio, ranked #1.

Lilly Endowment first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lilly Endowment held 90,376,978 shares of Eli Lilly worth $108B as of Q2 2026.
  • Lilly Endowment sold 1,520,000 Eli Lilly shares in Q2 2026, an estimated $1.55B.
  • Eli Lilly made up 100% of Lilly Endowment's portfolio in Q2 2026, its #1 holding.
  • Lilly Endowment first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lilly Endowment's 13F filing for Q2 2026, filed 23 Jul 2026.